PATENT CLAIM ANALYSIS

Application Number: 16404004
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["424", "489000"]

Abstract:
The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

Claim (Index 63):
The composition of  claim 58 , wherein the protein kinase inhibitor is dasatinib.

Metadata:
- Claim Count in Document: 161.0
- Percentile: 100.0
- Lexical Diversity: 1.48718
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16404027', '15791093', '15248107', '16403969', '16404059']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8812918238588945
- 35 USC 102 Novelty (BERT): 0.6956374690413049
- Combined Prediction Score: 0.8627263883771356
- Mean Citation Score: 844.9565640000003
- Max Citation Score: 849.7054
- Similarity Product: 692.4905014073372

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test